HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jankovic, J. Articles by Orman, J. Search for Related Content PubMed PubMed Citation Articles by Jankovic, J. Articles by Orman, J.

Botulinum A toxin for cranial-cervical dystonia

A double-blind, placebo-controlled study

Department of Neurology, Baylor College of Medicine, Texas Medical Center, Houston, TX.

We studied the effects of botulinum A toxin in 12 patients with blepharospasm and 10 patients with oromandibular-cervical dystonia received in a double-blind manner. All blepharospasm patients improved, 71.6% on a clinical rating score, 60.7% by self-assessment, and 38.9% by video-rating; there was no improvement with placebo. The beneficial effects lasted a mean of 12.5 weeks (range, 5 to 28). Only 37.5% of the patients with oromandibular-cervical dystonia improved. Patients with pharyngeal dystonia and spasmodic dysphonia also improved.

Address correspondence and reprint requests to Dr. Jankovic, Department of Neurology, Baylor College of Medicine, One Baylor Plaza, Texas Medical Center, Houston, TX 77030.

Supported by a grant from the Benign Essential Blepharospasm Research Foundation, Beaumont, TX.

Presented in part at the thirty-eighth annual meeting of the American Academy of Neurology, New Orleans, LA, April 1986.

Received April 25, 1986. Accepted for publication in final form July 18, 1986.

This article has been cited by other articles:

				D. M. Simpson, A. Blitzer, A. Brashear, C. Comella, R. Dubinsky, M. Hallett, J. Jankovic, B. Karp, C. L. Ludlow, J. M. Miyasaki, et al. Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology Neurology, May 6, 2008; 70(19): 1699 - 1706. [Abstract] [Full Text] [PDF]

				C. L. Comella, J. Jankovic, K. M. Shannon, J. Tsui, M. Swenson, S. Leurgans, W. Fan, and the Dystonia Study Group Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia Neurology, November 8, 2005; 65(9): 1423 - 1429. [Abstract] [Full Text] [PDF]

				J Jankovic Botulinum toxin in clinical practice J. Neurol. Neurosurg. Psychiatry, July 1, 2004; 75(7): 951 - 957. [Abstract] [Full Text] [PDF]

				B. A. Racette, G. Lopate, L. Good, S. Sagitto, and J. S. Perlmutter Ptosis as a remote effect of therapeutic botulinum toxin B injection Neurology, November 12, 2002; 59(9): 1445 - 1447. [Abstract] [Full Text] [PDF]

				D. J. Van Daele, E. M. Finnegan, R. L. Rodnitzky, W. Zhen, T. M. McCulloch, and H. T. Hoffman Head and Neck Muscle Spasm After Radiotherapy: Management With Botulinum Toxin A Injection Arch Otolaryngol Head Neck Surg, August 1, 2002; 128(8): 956 - 959. [Abstract] [Full Text] [PDF]

				E.-K. Tan and J. Jankovic Botulinum toxin A in patients with oromandibular dystonia: Long-term follow-up Neurology, December 1, 1999; 53(9): 2102 - 2102. [Abstract] [Full Text] [PDF]

				C. Sankhla, E. C Lai, and J. Jankovic Peripherally induced oromandibular dystonia J. Neurol. Neurosurg. Psychiatry, November 1, 1998; 65(5): 722 - 728. [Abstract] [Full Text]

				J. Jankovic and K. S. Schwartz Clinical Correlates of Response to Botulinum Toxin Injections Arch Neurol, December 1, 1991; 48(12): 1253 - 1256. [Abstract] [PDF]

				C. P. Harris, K. Alderson, J. Nebeker, J. B. Holds, and R. L. Anderson Histologic Features of Human Orbicularis Oculi Treated With Botulinum A Toxin Arch Ophthalmol, March 1, 1991; 109(3): 393 - 395. [Abstract] [PDF]